Bayer AG

Stock Exchange: XFRA • Ticker: BAYN • HQ: Leverkusen, Germany • Employees: 116,800

Ranking by technical area
Ranking by strategic pillar

Performance

Bayer falls two places, out of the top ten. Its modest improvements are frequently overshadowed by peers. It has made some improvements in how it measures progress toward access-related goals, and has time-bound targets tied to its R&D commitment to addressing neglected tropical diseases. Bayer is comparatively active in strengthening pharmacovigilance systems. Elsewhere, however, it has dropped: for example, it is comparatively less transparent than in 2014 about its market influencing activities and compliance efforts. Its equitable pricing and product registration performance has not kept pace with peers. Bayer provides limited evidence that it takes a pro-access approach to IP management. Bayer is engaged in large-scale structured donation programmes for Chagas disease and Human African Trypanosomiasis (HAT).

Change since 2014

Improves its measurements for tracking performance toward access targets, but it still lacks clear processes for incorporating local stakeholders’ perspectives in its access initiatives.

Has equitable pricing strategies for the same number of products as in 2014.

Has improved its accountability for its sales agents’ pricing practices, by providing pricing guidelines for all local sales agents.

Still does not publish its patenting approach.

Is less active in building capacity beyond the pharmaceutical value chain and in local manufacturing.

Continues to engage in donation programmes targeting Chagas disease and Human African Trypanosomiasis that cover all endemic countries.

Opportunities

Broaden access strategy beyond NTDs. Bayer can broaden its access strategy beyond neglected tropical diseases (NTDs) to include ischaemic heart disease, diabetes, lower respiratory infections and zoonotic diseases. In addition, Bayer can review its pipeline to assess the relevance of its R&D projects for people in low- and middle-income countries. For relevant projects, it can put access plans in place before products gain approval.

Develop an approach to local stakeholder engagement. Bayer can develop processes for selecting and engaging with local stakeholders to help ensure local needs are addressed through its R&D, capacity building and access management approaches. Local stakeholder engagement is crucial for understanding local needs and for responding with suitable, sustainable access strategies.

Expand application of equitable pricing. Bayer can apply the intra-country equitable pricing model that it uses for contraceptives to other products (e.g., vector-control products, and for NTDs) and to a range of countries in scope.

Give a public position on filing for and enforcing patents. Bayer can develop and disclose a public position on the filing for and enforcement of patents. Thirteen other companies in the Index have already taken this step. This would help give drug procurement agencies and generic manufacturers confidence about where Bayer would assert patent rights for current and future products. To complement this approach, Bayer can publicly disclose the status of its patents, clearly showing where products are on and off patent, and when patents are due to expire.

Join efforts to combat antimicrobial resistance. Bayer has three antibiotics on the WHO Model Essential Medicines List (EML) that are used in clinical practice and are important for low-resource settings. The company can increase access to these medicines, while ensuring their responsible use. Bayer can join global efforts to address antimicrobial resistance, for example by signing the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.

Sales and operations

Bayer reorganised its corporate structure in 2015. With the spin-off of Bayer MaterialScience (Covestro), its new corporate structure comprises three divisions (Pharmaceuticals, Consumer Health and Crop Science) and its Animal Health business unit. Its pharmaceuticals portfolio is focused on: cardiology, women’s healthcare, oncology, haematology, ophthalmology and radiology. CropScience has a broad portfolio of seeds and chemical and biological pest management solutions, including products for controlling and preventing vector-borne diseases. In 2014, the company acquired Merck & Co’s Consumer Care business for USD 14.2 bn. In 2016, Bayer signed a merger agreement with Monsanto for USD 66 bn. Bayer has a broad geographic presence, covering 102 of the countries in the scope of the Index.

Sales in countries in scope
Sales by division
Sales by region

Portfolio and pipeline

Bayer has a mid-sized portfolio of 34 relevant products and a small pipeline of three R&D projects that address the needs of people in countries in scope.

Its portfolio consists of 27 medicines and contraceptives, and seven vector-control products (all pesticides). Its vector-control products are all registered for the prevention of malaria and/or dengue. Bayer’s relevant medicine portfolio has a strong focus on contraceptive methods. The company is also active in infectious diseases, hypertensive and ischaemic heart disease.

Products per disease category

Approximately one third of Bayer’s portfolio targets women’s health, mainly via contraceptives.

Regarding its R&D pipeline, Bayer has a new R&D project to adapt emodepside for onchocerciasis, and is working on two adaptations of nifurtimox (Lampit®) for Chagas disease. The adaptations of nifurtimox have been in clinical development since at least 2014 (the previous Index), and clinical development of emodepside for use in humans began in December 2014. Bayer’s R&D projects target independently identified high-priority product gaps.

Pipeline projects

In December 2014, Bayer entered a product development partnership with the Drugs for Neglected Diseases initiative to develop emodepside for use in humans. Bayer has committed to providing this product at cost price.

First-line treatments and essential medicines

A comparatively high proportion of Bayer’s relevant products are listed on the WHO EML and/or considered first-line treatments. These include the contraceptives moxifloxacin (Avelox®) and nifurtimox (Lampit®).

Pipeline by stage of development
– Innovative medicines and vaccines

Bayer is not developing any innovative products for diseases in scope for use in low- and middle-income countries.

Pipeline by stage of development
– Adaptive medicines and vaccines

Bayer is adapting its veterinary medicine emodepside to treat onchocerciasis in humans. It is also adapting Lampit® for Chagas disease, developing a paediatric formulation and a shorter treatment regimen (to 60 and 30 days).

Please refer to the pdf of the report card (that can be downloaded here) for information on Bayer’s performance per technical area.

Sign up to receive updates about our work.